Sobieraj DM, et al. - The effects associated with long-acting muscarinic antagonists (LAMAs) versus placebo or other controllers as an add-on therapy to inhaled corticosteroids and the use of a LAMA as add-on therapy to inhaled corticosteroids and long-acting β-agonists (LABAs; hereafter referred to as triple therapy) versus inhaled corticosteroids and LABA in patients with uncontrolled, persistent asthma were determined. In this systematic review and meta-analysis, the use of LAMA versus placebo as add-on therapy to inhaled corticosteroids was shown to be associated with a lower risk of asthma exacerbations; however, the association of LAMA with benefit may not be greater than that with LABA. A lower risk of exacerbations was not evident in association with triple therapy.